Morquio B Disease Clinical Trial
Official title:
Natural History of Morquio B and Late-Onset GM1 Gangliosidosis
Mucopolysaccharidosis type IVB (Morquio-B disease, MBD) is an autosomal-recessive lysosomal
disease caused by mutations in a gene called GLB1. Clinically, Morquio B presents with
progressive skeletal deformities involving mostly long bones and spine. While the information
on GLB1 mutations associated with MBD is limited, there is a significant overlap in clinical
presentation between Morquio B and late-onset GM1 gangliosidosis with both conditions being
caused by mutations in the same GLB1 gene. In this study, the investigators plan to collect
retrospective data from patients' medical charts, as well as, information from the
prospective follow up clinic visits. There will be two study visits with the interval of one
year. The study procedures will include a detailed physical exam, bone scans, heart and lung
function, physical endurance tests, hearing test, laboratory tests and quality of life
surveys.
The purpose of this study is to collect data on the natural history of Morquio B and to
create a biobank of laboratory samples (blood, urine and skin cells) for future research.
This information will improve the understanding of the natural progression of Morquio B
disease.
The primary objective of this study is to establish the natural history of Morquio B
(Mucopolysaccharidosis type IVB, MBD) disease through the collection and analysis of
retrospective and prospective data on patients diagnosed with Morquio B. Because of
significant overlap in clinical presentation, patients with late-onset GM1 will also be
included.
Upon consent, data from clinical, laboratory, functional and quality of life studies, and
data from review of medical records will be collected and analyzed descriptively. In
addition, the samples of blood, urine and fibroblasts will be collected and stored at BC
Children Hospital Research Institute Biobank for future research. The prospective follow up
will include two clinic visits, one year apart. The following data will be collected during
the prospective observational part of the study (as per study protocol) and retrospective
part (whether such data are available from the medical chart):
- Medical history: Morquio B / Late-onset GM1 gangliosidosis diagnosis, presentation,
treatments and symptom progression
- Physical exam, including neurological and ophthalmological assessments
- Standard Grip Strength Evaluation
- Range of motion
- Six-minute walk test (6MWT)
- 3-Minute Stair Climb Test
- Gait and Motion assessment
- Pulmonary function testing
- Hearing test
- Echocardiography
- EKG
- X-ray (lumbar spine, upper & lower limbs, hip)
- DXA scan
- Brain MRI
- Laboratory tests (GAGs assay and pro-inflammatory cytokine panel)
- Blood, urine and fibroblast samples for biobanking
- Genetic test (if not done per standard of care)
Additional assessments and evaluations:
• Patient-reported outcomes: quality of life SF-36, MPS HAQ and the interview on personally
meaningful outcomes
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04624789 -
Registry Gangliosidoses
|
||
| Withdrawn |
NCT01457456 -
Biomarker for Morquio Disease (BioMorquio)
|